Edition:
United Kingdom

Perrigo Company PLC (PRGO.N)

PRGO.N on New York Stock Exchange

91.88USD
19 Jan 2018
Change (% chg)

$0.19 (+0.21%)
Prev Close
$91.69
Open
$92.00
Day's High
$92.23
Day's Low
$90.67
Volume
359,974
Avg. Vol
334,477
52-wk High
$92.75
52-wk Low
$63.69

Chart for

About

Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences. It manufactures OTC healthcare... (more)

Overall

Beta: 0.70
Market Cap(Mil.): $12,381.50
Shares Outstanding(Mil.): 142.61
Dividend: 0.16
Yield (%): 0.74

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Perrigo Says In Connection With Uwe Röhrhoff's Appointment As CEO, Co's Unit Perrigo DAC Entered Into Employment Agreement With Him

* PERRIGO COMPANY - IN CONNECTION WITH UWE RÖHRHOFF'S APPOINTMENT AS CEO, CO'S UNIT PERRIGO DAC ENTERED INTO AN EMPLOYMENT AGREEMENT WITH HIM

08 Jan 2018

Perrigo hires Gerresheimer ex-boss Rohrhoff as new CEO

Generic drugmaker Perrigo Company Plc appointed Uwe Rohrhoff, former CEO of Gerresheimer AG, as its new chief executive, the company said on Monday.

08 Jan 2018

UPDATE 1-Perrigo hires Gerresheimer ex-boss Rohrhoff as new CEO

Jan 8 Generic drugmaker Perrigo Company Plc appointed Uwe Rohrhoff, former CEO of Gerresheimer AG , as its new chief executive, the company said on Monday.

08 Jan 2018

Perrigo hires Gerresheimer ex-boss Rohrhoff as new CEO

Jan 8 Generic drugmaker Perrigo Company Plc appointed former Gerresheimer AG Chief Executive Uwe Rohrhoff as its new president and CEO, the company said on Monday.

08 Jan 2018

BRIEF-Perrigo appoints Uwe Röhrhoff as CEO

* PERRIGO APPOINTS UWE RÖHRHOFF AS PRESIDENT & CHIEF EXECUTIVE OFFICER

08 Jan 2018

BRIEF-Perrigo Announces Tentative FDA Approval For The Generic Version Of Prolensa Ophthalmic Solution 0.07%

* PERRIGO ANNOUNCES TENTATIVE FDA APPROVAL FOR THE GENERIC VERSION OF PROLENSA® OPHTHALMIC SOLUTION 0.07% Source text for Eikon: Further company coverage:

03 Jan 2018

BRIEF-Perrigo Announces The Launch Of An AB Rated Generic Version Of Mycolog II Cream

* PERRIGO ANNOUNCES THE LAUNCH OF AN AB RATED GENERIC VERSION OF MYCOLOG II CREAM Source text for Eikon: Further company coverage:

27 Nov 2017

BRIEF-Perrigo Company ‍Launch AB Rated Generic Version Of Exalgo 32mg

* PERRIGO COMPANY PLC - ‍LAUNCH OF AN AB RATED GENERIC VERSION OF EXALGO 32MG EXTENDED RELEASE TABLETS C-II​ Source text for Eikon: Further company coverage:

27 Nov 2017

BRIEF-Perrigo Company completes divestiture of API business for $110 million

* Perrigo Company completes divestiture of API business for $110 million Source text for Eikon: Further company coverage:

21 Nov 2017

BRIEF-Perrigo Q3 GAAP EPS $0.31

* Perrigo Company PLC reports third quarter 2017 financial results

09 Nov 2017

Earnings vs. Estimates